The Recall Desk

Category

Drug recalls

FDA recalls of prescription and over-the-counter drugs.

About drug recalls

FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.

The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.

If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.

3501–3525 of 5139

  • ModerateFDA (Drugs)·D-1306-2022·2022-08-17

    Glenmark Pharmaceuticals Recalls Telmisartan/Hydrochlorothiazide Due to Defective Blister Packs

    Glenmark Pharmaceuticals Inc., USA is recalling specific lots of Telmisartan and Hydrochlorothiazide tablets due to complaints of defective blister packs that are difficult to open and cause tablets to break during removal.

    Product
    TELMISARTAN AND HYDROCHLOROTHIAZIDE — TELMISARTAN AND HYDROCHLOROTHIAZIDE (TELMISARTAN AND HYDROCHLOROTHIAZIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1333-2022·2022-08-10

    SANGTER Energy Supplement Capsules Recalled for Undisclosed Sildenafil

    Distributor RFR, LLC is recalling SANGTER Energy Supplement Capsules because FDA analysis found they contain undisclosed sildenafil without FDA approval. The product was distributed nationwide and internationally.

    Product
    SANGTER Energy Supplement Capsules, 3000mg x 7 grain, 7-count blister pack within a carton, Distributed by: Distributor RFR, LLC, (800) 519-0204 Miami 33172 FL, USA; UPC 0 705632 523285
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1350-2022·2022-08-10

    SUSTANGO supplement capsules recalled for undisclosed tadalafil content

    SUSTANGO capsules contain the undisclosed pharmaceutical ingredient tadalafil and were marketed without FDA approval. Approximately 750 cartons were distributed nationwide via Amazon.

    Product
    SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1300-2022·2022-08-10

    Naftifine Hydrochloride Gel recalled for failed impurity specifications

    Tolmar Inc. recalls Naftifine Hydrochloride Gel 1% due to out-of-specification impurity test results. The recalled tubes may contain unidentified impurities that exceed acceptable limits.

    Product
    Naftifine Hydrochloride Gel, USP 1%, packaged in cartons with: a) Net Wt. 90g tube (NDC 0115-1510-48), b) Net Wt. 40g tube (NDC 0115-1510-63), c) Net Wt. 60g tube (NDC 0115-1510-58), Rx only, Manufactured by: Tolmar, Inc., Fort Collins, CO, 80526, Distributed by: Amneal Pharmace
    Category
    Drug
    Distribution
    1 state
  • HighFDA (Food)·F-1533-2022·2022-08-10

    Vicks Children's Botanicals Liquid Supplement Recalled for Improper Processing

    The Procter & Gamble Company is recalling Vicks Children's Botanicals Liquid Combo Pack because the acidified/low acid dietary supplement was manufactured without an FDA-approved process.

    Product
    Vicks Children's Botanicals Liquid Daytime/Nighttime Combo Pack 4oz plastic bottles
    Category
    Drug
    Distribution
    0 states
  • HighFDA (Food)·F-1535-2022·2022-08-10

    Vicks Children's Botanicals Liquid Nighttime Recalled for Improper Processing

    The Procter & Gamble Company is recalling Vicks Children's Botanicals Liquid Nighttime due to manufacturing without an approved acidification process. The product's preservation safety cannot be assured.

    Product
    Vicks Children's Botanicals Liquid Nighttime 4oz plastic bottle
    Category
    Drug
    Distribution
    0 states
  • HighFDA (Food)·F-1534-2022·2022-08-10

    Vicks Children's Botanicals Recalled for Unapproved Acidification Process

    The Procter & Gamble Company is recalling Vicks Children's Botanicals Liquid Daytime dietary supplement due to use of an unapproved acidification process. The product was distributed to 42 states in approximately 34,526 cases.

    Product
    Vicks Children's Botanicals Liquid Daytime 4oz plastic bottle
    Category
    Drug
    Distribution
    0 states
  • HighFDA (Drugs)·D-1302-2022·2022-08-10

    Prescription Drug Matzim LA Extended-Release Tablets Recalled for Failed Dissolution

    Teva Pharmaceuticals is recalling Matzim LA (Diltiazem Hydrochloride) 180 mg tablets because they failed to meet dissolution specifications. The recall affects approximately 8,022 bottles distributed nationwide in the United States and Puerto Rico.

    Product
    MATZIM LA — MATZIM LA (DILTIAZEM HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1303-2022·2022-08-10

    Matzim LA Extended-Release Tablets Recalled for Dissolution Specification Failure

    Matzim LA Extended-Release Tablets, 240 mg are being recalled due to failed dissolution specifications. Patients taking this medication should consult their doctor about their treatment.

    Product
    Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.
    Category
    Drug
    Distribution
    Distributed nationwide
  • LowFDA (Drugs)·D-1304-2022·2022-08-10

    Tacrolimus Ointment Recalled for Defective Containers That Split

    Glenmark Pharmaceuticals is recalling Tacrolimus Ointment 0.1% because tubes may split at the side seam. The recall affects over 654,000 units distributed nationwide.

    Product
    TACROLIMUS — TACROLIMUS (TACROLIMUS)
    Category
    Drug
    Distribution
    Distributed nationwide
  • CriticalFDA (Drugs)·D-1292-2022·2022-08-03

    Insulin Glargine Prefilled Pens Recalled for Missing Label

    Mylan Pharmaceuticals is recalling Insulin Glargine prefilled pens (lot BF21002895) distributed nationwide because some pens lack labels, which could prevent patients from properly identifying and administering the medication.

    Product
    Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specia
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1286-2022·2022-08-03

    Nifedipine WSP Ointment Recalled Due to Potency Variability

    Valor Compounding Pharmacy is recalling Nifedipine WSP 0.2% Ointment due to potency variability. Some batches may be subpotent or superpotent, affecting safety and efficacy.

    Product
    Nifedipine WSP 0.2% Ointment, 60 gram tubes, Rx only, Valor Compounding Pharmacy, 2461 Shattuck Ave., Berkeley, CA 94704
    Category
    Drug
    Distribution
    1 state
  • HighFDA (Drugs)·D-1287-2022·2022-08-03

    Lansoprazole tablets recalled nationwide due to failed dissolution specifications

    Dr. Reddy's Laboratories is recalling Lansoprazole 15-mg delayed-release tablets nationwide due to failed dissolution specifications. The tablets may not dissolve properly, potentially affecting medication effectiveness.

    Product
    LANSOPRAZOLE — LANSOPRAZOLE (LANSOPRAZOLE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1291-2022·2022-08-03

    FDA Recalls Divalproex Sodium Tablets for Failed Dissolution Specifications

    Sun Pharmaceutical recalls Divalproex Sodium delayed-release tablets due to failed dissolution specifications discovered during stability testing. The tablets may not dissolve as intended.

    Product
    DIVALPROEX SODIUM — DIVALPROEX SODIUM (DIVALPROEX SODIUM)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1293-2022·2022-08-03

    Irbesartan Blood Pressure Tablets Recalled Due to Failed Dissolution

    Jubilant Cadista is recalling 9,600 bottles of Irbesartan Tablets (150mg) nationwide due to failed dissolution specifications. Affected lot IB220023A expires 08/2022.

    Product
    IRBESARTAN — IRBESARTAN (IRBESARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1289-2022·2022-08-03

    Prescription testosterone gel recalled due to out-of-specification potency

    Teva Pharmaceuticals is recalling testosterone gel lot 1403180 after stability testing revealed out-of-specification assay results indicating superpotency. The affected 12,354 cartons were distributed nationwide.

    Product
    TESTOSTERONE — TESTOSTERONE (TESTOSTERONE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1294-2022·2022-08-03

    Jubilant Cadista Irbesartan tablets recalled due to failed dissolution

    Jubilant Cadista Pharmaceuticals is recalling 28,560 bottles of Irbesartan 75 mg tablets nationwide due to failed dissolution specifications that may compromise drug efficacy.

    Product
    IRBESARTAN — IRBESARTAN (IRBESARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-1298-2022·2022-08-03

    Juice Beauty Lip Moisturizer recalled for failed dissolution specifications

    Eco Lips, Inc. is recalling Juice Beauty The Organic Solution SPF 8 Joyful Lip Moisturizer (15,313 tubes) because the product failed dissolution specifications. Affected units were distributed in California.

    Product
    Juice Beauty, The Organic Solution, SPF 8, Joyful Lip Moisturizer, Hydratant pour les Levres, NET WT 0.15 oz (4.25 g) per tube, Active Ingredient: Zinc oxide 4%, Manufactured for Juice Beauty, Inc., 709 Fifth Ave., San Rafael, California 94901-3566
    Category
    Drug
    Distribution
    1 state
  • ModerateFDA (Drugs)·D-1290-2022·2022-08-03

    Crest 3D White Toothpaste recalled for missing label and wrong formulation

    Procter & Gamble is recalling Crest 3D White Fluoride Anticavity Toothpaste because some tubes lack labels and contain a different formulation than indicated. About 1,128 tubes distributed in Washington State are affected.

    Product
    Crest 3D White Fluoride Anticavity Toothpaste, Advanced Triple Whitening, 0.243% sodium fluoride, Net Wt. 5.6 oz (158 g) a) Individual carton, UPC 0 37000 598534; b) 5-count Bundle, UPC 037000171867, Distributed. By Procter & Gamble, Cincinnati, OH 45202.
    Category
    Drug
    Distribution
    0 states
  • LowFDA (Drugs)·D-1299-2022·2022-08-03

    Juice Beauty lip moisturizer recalled for failed dissolution specifications

    Juice Beauty The Organic Solution SPF 8 lip moisturizer is being recalled due to failed dissolution specifications. The recall affects 35,313 tubes distributed in California.

    Product
    Juice Beauty, The Organic Solution, SPF 8, Naturally Clear Lip Moisturizer, Hydratant pour les Levres, NET WT 0.15 oz (4.25 g) per tube, Active Ingredient: Zinc oxide 4%, Manufactured for Juice Beauty, Inc., 709 Fifth Ave., San Rafael, California 94901-3566
    Category
    Drug
    Distribution
    1 state
  • SevereFDA (Drugs)·D-1296-2022·2022-07-27

    Ortiga mas Ajo Rey supplement recalled for undeclared diclofenac

    FDA recalls Ortiga mas Ajo Rey dietary supplement sold nationwide due to undeclared diclofenac. Product marketed as supplement contains pharmaceutical ingredient not listed on label.

    Product
    Ortiga mas Ajo Rey Reforzado con Omega 3, 6 y 9, is packaged in a carton containing 30 tablets (500 mg c/u) in a bottle and 60 capsules (400 mg c/u) in a bottle, Hecho en Mexico por: Omega Nutrition , Jorge Washington No. 108 Col. Las Americas, Hidalgo del Parral, Chihuahua. C.P
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1337-2022·2022-07-27

    FDA Recalls Launch Sequence Euphoria Capsules for Undeclared Tadalafil

    Launch Sequence Euphoria Capsules have been recalled because the product contains undeclared tadalafil, an unapproved active ingredient. The capsules were distributed nationwide in the USA and Canada.

    Product
    Launch Sequence Euphoria Capsules, 10- count tins, ASIN B08ZJX4V9J, UPC Code 661020846864.
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1295-2022·2022-07-27

    Artri Ajo King Tablets Recalled Due to Undeclared Diclofenac

    The FDA is recalling Artri Ajo King tablets nationwide after finding they contain undeclared diclofenac, a prescription anti-inflammatory drug. Affected bottles (lot LTARTKNGOMG30220, expiring December 2025) were sold on Amazon.

    Product
    Artri Ajo King Reforzado con Ortiga y Omega 3 tablets, 500 mg, 100-count bottle, Hecho en Mexico por: PLANTAS MEDICINALES DE MEXICO , Melchor Ocampo No. 55 Local D, Delegacion Xochimilco. C.P. 16800, Mexico, D.F., ASIN B092P4615M, UPC 7 501031 111190
    Category
    Drug
    Distribution
    Distributed nationwide

Looking for a different category? Browse all recalls.